Ublituximab + Ibrutinib in Select B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma
DRUG: Ublituximab|DRUG: Ibrutinib
To evaluate the safety of ublituximab in combination with ibrutinib in patients with select B-cell malignancies, To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities, 28 days (1 cycle of therapy)
Overall Response Rate, To assess the overall response rate (ORR) in patients with hematologic malignancies treated with Ublituximab in combination with Ibrutinib, Up to 1 year
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.